PHIA Koninklijke Philips N.V.

Philips launches pre-hospital wireless monitoring solution for emergency medical response in U.S.

Philips launches pre-hospital wireless monitoring solution for emergency medical response in U.S.

July 29, 2020

  • Philips receives 510(k) clearance from the FDA for its professional defibrillator (Tempus LS- Manual), now offering its remote monitor and defibrillator solution (Tempus ALS) to EMS customers in the U.S.
  • Solution delivers real-time bidirectional data transfer for remote patient monitoring, giving EMS responders a new approach to pre-hospital care

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of its remote monitoring and defibrillator solution (Tempus ALS) for pre-hospital settings in the U.S. The solution is a complete end-to-end system that combines innovative hardware and advanced software to expand the pre-hospital scope of care for first responders. The professional defibrillator (Tempus LS-Manual) is the final element of the overall solution to receive 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for sale in the U.S. market.

As a unique modular platform, the (Tempus ALS) consists of a remote portable vital signs patient monitor (Tempus Pro), and remote professional defibrillator (Tempus LS-Manual). While the monitor and defibrillator can be used separately, the devices also connect wirelessly to share data and transfer vitals, waveforms and images into Philips web-based software platform (IntelliSpace Corsium). The software platform provides robust, real-time transfer of clinical data and events, interactive ECG measurement, two-way communication and more, enabling rapid clinical and transport decision support and seamless electronic patient care recording (ePCR) integration outside the hospital in emergency settings.

“In emergency situations, where seconds count, having access to advanced patient data collection and sharing and real-time secure data streaming, can help inform confident treatment and transport decisions outside the hospital,” said Arman Voskerchyan, General Manager of Therapeutic Care at Philips. “The integrated remote monitoring and defibrillator solution combined with our web-based software platform will help front line responders provide emergency care, diagnosis and treatment - including defibrillation therapy, data management and clinical and operational efficiency features – in a fully integrated solution.”

Emergencies and care events outside the hospital continue to rise, with an estimated 240 million calls made to 9-1-1 in the U.S. each year [1]. In addition to the stress of the unknown and what to expect at the scene of the call, emergency medical providers must deal with manual handling issues. Equipment carried is heavy, often damaged due to use in unpredictable conditions and has limited data connectivity – inhibiting the ability for on-scene support. In an effort to address these challenges, both elements of the Philips remote monitoring and defibrillator (Tempus ALS) solution are designed with a small, rugged exterior and long-lasting battery to allow emergency medical providers to focus on caring for the patient without the hassle or distraction of bulky equipment.

Philips leadership in Emergency Care solutions

Earlier this year, Philips launched its new in the U.S. market, previously in use in Europe, helping care teams spot life-threatening conditions remotely, improve accuracy of support from on-scene crews, and enhance tailoring of in-hospital care based on pre-hospital physiology. In October 2019, Philips  where helicopter Emergency Service (HEMS) teams were able to live stream patient medical information from the scene to the hospital through the Philips pre-hospital solution. Philips offers a wide range of emergency care offerings, including automated external defibrillators (AEDs), advanced life support monitors, and more. Visit for more information on the remote monitoring and defibrillator solution and Philips broad portfolio of Emergency Care solutions.

[1]

For further information, please contact:

Kathy O'Reilly 

Philips Global Press Office

Tel:

E-mail : 

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



 

Attachments

EN
29/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips successfully prices offering of Notes for EUR 1 billion to be ...

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects May 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any ...

 PRESS RELEASE

Philips Future Health Index 2025: AI poised to transform global health...

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, , highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. H...

Koninklijke Philips N.V.: 1 director

A director at Koninklijke Philips N.V. bought 8,176 shares at 24.410USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch